Lilly's Zepbound was associated with more weight loss than Wegovy HD in an indirect comparison
LLY•An indirect treatment comparison found that Zepbound 10 mg and 15 mg were associated with more weight loss than Wegovy HD. At 72 weeks, Zepbound users achieved 20.2% weight reduction versus 13.7% for Wegovy; 15 mg showed 4.5% greater weight loss than Wegovy HD.
1. Weight-loss comparison
An indirect treatment comparison found that Lilly’s Zepbound at 10 mg and 15 mg was associated with more weight loss than Wegovy HD, which uses a 7.2 mg semaglutide injection. At 72 weeks, Zepbound users achieved 20.2% weight reduction versus 13.7% for Wegovy.
2. Dose and safety findings
Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity and more than three times the odds of achieving 20% weight reduction. Zepbound 10 mg and 15 mg had comparable adverse-event discontinuation rates to Wegovy HD.
